Skip to content

Personalized Modulation of Microbiota

Personalized Modulation of the Microbiota Through the Intelligent Design of Foods and Ingredients Based on Enterotype-Based Diagnosis (NUTRIBIOTA). Nutritional Intervention in Humans

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04799223
Acronym
NUTRIBIOTA
Enrollment
60
Registered
2021-03-16
Start date
2020-11-15
Completion date
2021-05-15
Last updated
2023-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Microbial Colonization, Nutrition Disorders, Obesity

Keywords

Obesity, Fecal microbiota, Nutrition, Diet, Insulin

Brief summary

Intestinal flora or microbiota is the group of bacteria that live in the intestine, in a symbiotic relationship with the human body. It is estimated that human beings have around 2,000 different bacteria species. The gut microbiota plays a key in many of the body's functions. Hence, the analysis of the gut microbiome provides insight into the state of the microbiota as an indicator of overall health due to its metabolic, protective and nutritional functions. A balanced diet promotes the formation and maintenance of a well-structured microbiota, in which the different species of microorganisms cohabit in a balanced and controlled system. The study is based on the hypothesis that the intake of certain plant-based foods rich in various active ingredients (especially non-digestible carbohydrates, certain types of fats and polyphenols) can modulate the microbiota and thus improve the health status of the human population. Taking into account this background, the objective of this study is to assess the effect of the inclusion of functional foods and ingredients within a balanced diet on the composition of the microbiota and also on health parameters associated with metabolic disease.

Detailed description

The 60 volunteers participating in the study who meet the inclusion criteria, will be randomly divided into two groups: * Control group (nutritional promotion): volunteers will be provided with basic nutritional recommendations based on a Mediterranean diet. * Experimental group (Nutribiota): volunteers will be instructed to follow a dietary strategy similar to the control group, but including the functional foods and ingredients developed by the companies with the aim to promote a balanced and specific diet associated with improvements in the composition of the microbiota and metabolic parameters of the volunteers. The duration of the study are 8 weeks, during which 4 visits are scheduled: * Recruitment: this visit will consist on an initial screening in which the volunteers will be informed about the characteristics of the study and will be receive the information sheet and the informed consent form to be signed by all those interested in participating in the study. Volunteers who meet the inclusion for the study will be asked to complete the Food Frequency Questionnaire and Physical Activity Questionnaire for the next visit (visit 1). In addition, each participant will be provided with a faecal microbiota sample collection kit which they will have to hand in with the corresponding sample at the next visit (visit 1). * Clinical investigation day 1 (week 0):after a fasting period of at least 10 hours, the nursing staff will take a blood sample to analyze the biochemical parameters and metabolomic profile. Anthropometric measurements will be taken from each volunteer (weight, height, waist and hip circumference, and body composition analysis by bioimpedance) with the collaboration of a dietician. In addition, faecal sample and Food Frequency Questionnaire and Physical Activity Questionnaire will be collected. Volunteers randomly assigned to the experimental group will be given the dishes and functional ingredients designed by the companies, which they will have to incorporate into a balanced dietary pattern following the indications given by the dietician. * Clinical investigation day 2 (week 4): In this visit, the adherence of the volunteers to the study will be monitored and the weight of the volunteers will be registered. In addition, all study volunteers will be given a faecal microbiota sample collection kit, which should be handed in with the corresponding sample at the final visit. Moreover, Food Frequency Questionnaire and Physical Activity Questionnaire will be given to each volunteer in order to be filled for the final visit. Volunteers who belong to the experimental group will be given dishes and functional ingredients. * Clinical investigation day 3 (week 8): Faecal sample, Food Frequency Questionnaire and Physical Activity Questionnaire will be collected. The procedures in this visit will be the same as in visit 1, but dishes and functional ingredients will not be given to the volunteers.

Interventions

OTHERFour-foods eating guidelines

To follow a healthy eating pattern and consume four (4) foods designed for the study (extra virgin olive oil with olive leaf extract, chickpea dish with spinach, vegetable cream dish, and olive fiber) and to follow a healthy eating pattern.

OTHERNo designed-foods eating guidelines

To follow a healthy eating pattern. Their diet is not accompanied by the four newly designed foods of the other group.

Sponsors

Clinica Universidad de Navarra, Universidad de Navarra
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Volunteers of both sexes with ages between 20 and 65 years. * Volunteers with a body mass index between 24.9 and 34.9 kg / m2. * Volunteers with intestinal dysbiosis. * Physical examination and normal vital signs or clinically irrelevant for the study. * Subjects must be able to understand and be willing to sign the informed consent.

Exclusion criteria

* Volunteers who have taken antibiotics or corticosteroids one month before the start of the intervention or antihistamines 15 days before the start of the intervention. * Volunteers who are taken gastric protectors chronically. * Volunteers who present changes in their pharmacological treatment in the last 3 months before the start of the study. * Volunteers with intestinal pathologies (ulcerative colitis, Crohn's disease, or similar). * Volunteers suffering from Covid-19

Design outcomes

Primary

MeasureTime frameDescription
Change of fecal microbiota compositionThe Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention).Measured by analyzing the variable regions V3-V4 of the prokaryotic 16S rRNA (ribosomal ribonucleic acid) gene sequences, which gives 460 bp amplicons in a two-round PCR protocol. The kit used will be the Nextera® XT DNA Index Kit, FC-131-1002 (Illumina, San Diego, CA, USA). In the first step, PCR is used to amplify a template out of a DNA fecal sample using specific primers from Illumina. Then, sequencing libraries are built with the MiSeq® Reagent Kit v3 (600 cycles) MS-102-3003 (Illumina). Finally, paired-end sequencing is performed on a MiSeq platform (Illumina) with a 600 cycles Miseq run. Fecal samples are self-collected by the volunteers' fecal samples using OMNIgene.GUT kits from DNA Genotek (Ottawa, ONT, Canada), according to the standard instructions provided by the company

Secondary

MeasureTime frameDescription
Change of total cholesterol concentrationThe Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention).Total cholesterol concentration will be reported in mg/dl
Change of LDL-cholesterol concentrationThe Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention).LDL-cholesterol concentration will be reported in mg/dl by Friedewald equation.
Change of HDL-cholesterol concentrationThe Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention).HDL-cholesterol concentration will be reported in mg/dl
Change of triglyceride concentrationThe Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention).Triglyceride concentration will be reported in mg/dl
Change of aspartate aminotransaminase concentrationThe Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention).Aspartate aminotransaminase concentration will be reported in mg/dl
Change of alanine aminotransferase concentrationThe Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention).Alanine aminotransferase concentration will be reported in U/L
Change of insulin concentrationClinical The Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention).day 1 and 3Insulin concentration will be reported in U/L
Change of glucose concentrationThe Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention).Glucose concentration will be reported in mg/dl
Change of body mass indexThe Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention).Body weight will be reported in kg
Change of body fat mass percentageThe Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention).Body fat mass will be reported in percentage
Change of body lean massThe Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention).Body lean mass will be reported in kg
Change of body water percentageThe Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention).Body water will be reported in percentage
Change of visceral fat levelThe Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention).Visceral fat level will be reported
Change of physical activityThe Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention).Physical activity level will be monitored by physical activity questionnaire
Change of dietary intakeThe Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention).Dietary energy and macronutrient intake will be monitored by a food frequency questionnaire
Change of body weightThe Time Frame contains two time points: day 1 (at baseline) compared to day 3 (after 8 weeks of dietary intervention).Body weight will be reported in kg

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026